A review of studies of hormonal adjuvant therapy in prostate cancer
- PMID: 10529561
- DOI: 10.1159/000052338
A review of studies of hormonal adjuvant therapy in prostate cancer
Abstract
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die from the disease despite undergoing therapy with curative intent. Several retrospective studies suggest that adjuvant hormonal therapy may improve long-term outcome after radical surgery in men with positive lymph nodes, although this approach has yet to be studied in a prospective setting. No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed, but in an interim analysis of an open controlled trial, adjuvant flutamide significantly improved progression-free survival at 4 years. Three prospective studies in the radiotherapy setting have shown that adjuvant luteinizing hormone-releasing hormone (LH-RH) agonist therapy significantly improves progression-free and/or overall survival. Future studies need to define patient subgroups who will benefit most from adjuvant therapy. The side effects of the different therapeutic options also need to be compared. It is hoped that many of the outstanding questions concerning adjuvant hormonal therapy will be answered by the ongoing Bicalutamide Early Prostate Cancer Programme.
Similar articles
-
Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.Curr Treat Options Oncol. 2003 Oct;4(5):351-62. doi: 10.1007/s11864-003-0036-5. Curr Treat Options Oncol. 2003. PMID: 12941195 Review.
-
[Keyrole of endocrinology in the victory against prostate cancer].Bull Cancer. 2006 Sep;93(9):949-58. Bull Cancer. 2006. PMID: 16980238 Review. French.
-
Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.Int J Urol. 2004 Jun;11(6):397-401. doi: 10.1111/j.1442-2042.2004.00819.x. Int J Urol. 2004. PMID: 15157209
-
[Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].Arch Esp Urol. 1996 Oct;49(8):797-806. Arch Esp Urol. 1996. PMID: 9065276 Clinical Trial. Spanish.
-
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.Br J Urol. 1997 Feb;79(2):226-34. doi: 10.1046/j.1464-410x.1997.33215.x. Br J Urol. 1997. PMID: 9052475
Cited by
-
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.Cochrane Database Syst Rev. 2019 Jun 11;6(6):CD003506. doi: 10.1002/14651858.CD003506.pub2. Cochrane Database Syst Rev. 2019. PMID: 31194882 Free PMC article.
-
Cancer treatment using peptides: current therapies and future prospects.J Amino Acids. 2012;2012:967347. doi: 10.1155/2012/967347. Epub 2012 Dec 20. J Amino Acids. 2012. PMID: 23316341 Free PMC article.
-
Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.Curr Treat Options Oncol. 2003 Oct;4(5):351-62. doi: 10.1007/s11864-003-0036-5. Curr Treat Options Oncol. 2003. PMID: 12941195 Review.
-
Value of endocrine therapy for early and locally advanced prostate cancer.Drugs Aging. 2003;20(2):115-24. doi: 10.2165/00002512-200320020-00003. Drugs Aging. 2003. PMID: 12534312 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical